By: Michelle Hoiseth, Chief Data Officer, PAREXEL and Leanne Larson, Corporate Vice President and WW Head, Real-World Evidence, PAREXEL The current process of drug development is on an unsustainable path forward. The system is inefficient, lengthy and costly. Despite the ris … Read More »

Many, if not most, patients who are treated for cancer or leukemia successfully clear their disease and achieve what is called “remission.” Unfortunately, in most types of cancer, more than half of those who are in remission then go on to relapse; i.e. the cancer returns.  C … Read More »

A sizeable population of physicians in US is now demanding Real World Evidence (RWE) from the pharma industry in order to move prescriptions. This was revealed in the latest edition of PharmaFutureTM Digital Savvy HCP Survey. Physicians are moving the traditional information … Read More »

By: Kathleen Hoffman, PhD MSPH Recently, an industry client asked Inspire to conduct an exploratory social listening project to learn more about patients living with a rare immune disorder. In patients’ real-world online conversations, we identified a focus on dietary change … Read More »

by Martin Roessner, MS, Corporate Vice President, Biostatistics, PAREXEL The current state of pharmaceutical drug development is not on a sustainable path forward. Many experts believe that the process is inefficient, lengthy and costly. The average time it takes to bring a … Read More »

By Jamie Peck, Managing Director, iON Life sciences is a data-driven market, from clinical data to real-world evidence. Healthcare systems, HCPs, advocacy groups, and patients seek relevant, credible, and actionable information to inform decision-making. Traditionally, conte … Read More »

By: Sy Pretorius, Chief Scientific & Medical Officer, PAREXEL Drug development today is facing serious challenges. The way new treatments are brought to market has become increasingly inefficient, lengthy and costly, with a high likelihood of failure. Meanwhile, pressure … Read More »

Perhaps the single most important consideration in selecting a site is whether it can make its enrollment. Many don’t; in fact, 20-25 percent of all clinical studies close because they fail to meet enrollment targets.1 For decades, sponsors have found their “best fit” sites … Read More »

More than one in four life sciences companies expect large-scale transformation in the next three years. Are you one of them? Large pharma companies know to remain competitive they have to transform By: Joy Taylor, Co-Founder and CEO John Cassimatis, Co-Founder and President … Read More »

Pfizer, Merck, AstraZeneca Maintain Lead in Brand Recall and Net Promoter Scores By Gaurav Kapoor, co-founder and EVP, Indegene, a leading global healthcare solutions provider Content tracking and optimization of direct-to-consumer websites has earned Lilly and Teva top hono … Read More »

Article by Manish Gupta, co-founder and CEO, Indegene, a leading global healthcare solutions company As lifesciences companies seek to “Amazonize” their physician and patient engagement and progress on their journey to deliver customized omni-channel experience to their cust … Read More »

Article by Gaurav Kapoor, co founder and EVP, Indegene, a global healthcare solutions company In the recent months, there has been a lot of speculation about Amazon’s entry into the pharmaceutical sector. Given Amazon’s track record of disrupting and displacing established p … Read More »

On Oct. 12 Healthcare Businesswomen’s Association hosted a panel exploring the successes and failures of business transformation in life sciences. The panelists, who have all thankfully lived to tell the tale, shared their transformation do’s and don’ts based on pitfalls and … Read More »

TayganPoint Consulting Group conducted its inaugural survey this year in collaboration with Pharma Voice.  The intent of the survey was to explore the many issues Life Science Companies face as they transform and better understand how well they are prepared for driving trans … Read More »

Congress recently passed the 21st Century Cures Act with $4.8 billion dollars in funding and a purpose of speeding the development and approval of new medicines and medical devices the act has generated significant excitement and discussion.  Some of the key components of th … Read More »